References

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

10.1056/nejmoa053422 · 2006 · External reference

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

10.1016/s1470-2045(09)70311-0 · 2010 · External reference

Platinum-based chemotherapy plus cetuximab in head and neck cancer

10.1056/nejmoa0802656 · 2008 · External reference

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy

10.1200/jco.2006.06.7447 · 2007 · External reference

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

10.1016/j.oraloncology.2014.12.011 · 2015 · External reference

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

10.4161/cbt.11.9.15050 · 2011 · External reference

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

2001 · External reference

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy

10.1158/1078-0432.ccr-1100-03 · 2004 · External reference

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells

10.1158/1078-0432.ccr-07-4905 · 2008 · External reference

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

10.1038/onc.2008.19 · 2008 · External reference

Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma

10.1371/journal.pone.0012702 · 2010 · External reference

Nuclear EGFR contributes to acquired resistance to cetuximab

10.1038/onc.2009.234 · 2009 · External reference

Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab

10.1158/0008-5472.can-07-0589 · 2007 · External reference

Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer

10.1158/1078-0432.ccr-11-0861 · 2011 · External reference

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells

10.1158/0008-5472.can-07-2460 · 2008 · External reference

Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells

10.1016/j.canlet.2010.04.006 · 2010 · External reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

10.1126/science.1141478 · 2007 · External reference

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

10.1038/nature05474 · 2007 · External reference

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

10.1158/0008-5472.can-09-3145 · 2010 · External reference

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

10.1073/pnas.1016140108 · 2011 · External reference

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

10.1073/pnas.1018001108 · 2012 · External reference

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas

10.1158/2159-8290.cd-12-0531 · 2013 · External reference

AXL mediates resistance to cetuximab therapy

10.1158/0008-5472.can-14-0294 · 2014 · External reference

AXL is a logical molecular target in head and neck squamous cell carcinoma

10.1158/1078-0432.ccr-14-2648 · 2015 · External reference

Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade

10.1016/j.ijrobp.2005.04.028 · 2005 · External reference

Enhancement of radiation response with bevacizumab

10.1186/1756-9966-31-37 · 2012 · External reference

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

10.1093/annonc/mds245 · 2013 · External reference

Long-term outcomes of bevacizumab and chemoradiation for locoregionally advanced nasopharyngeal carcinoma: a nonrandomized controlled trial

10.1001/jamanetworkopen.2023.16094 · 2023 · External reference

Reprogramming the immunological microenvironment through radiation and targeting Axl

10.1038/ncomms13898 · 2016 · External reference

Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer

10.1158/1078-0432.ccr-16-2586 · 2017 · External reference

AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer

10.1158/1078-0432.ccr-19-3142 · 2020 · External reference

Triple-negative breast cancer cells that survive ionizing radiation exhibit an Axl-dependent aggressive radioresistant phenotype

10.3892/etm.2023.12147 · 2023 · External reference

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

10.1016/j.canlet.2008.04.017 · 2008 · External reference

Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes

10.1111/cas.12171 · 2013 · External reference

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer

10.18632/oncotarget.17026 · 2017 · External reference

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells

10.18632/oncotarget.360 · 2011 · External reference

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

10.1038/ng.2330 · 2012 · External reference

The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells

10.1126/scisignal.2004155 · 2013 · External reference

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

10.1038/onc.2015.343 · 2016 · External reference

AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers

10.1158/1541-7786.mcr-16-0157 · 2017 · External reference

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia

10.3324/haematol.2021.278369 · 2022 · External reference

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis

10.1016/j.phrs.2023.106668 · 2023 · External reference

Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer

10.1016/j.lfs.2023.122230 · 2023 · External reference

Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable

10.1158/1078-0432.ccr-23-0163 · 2024 · External reference

AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma

10.1038/s41388-023-02810-7 · 2023 · External reference

AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer

10.1158/0008-5472.can-23-1459 · 2024 · External reference

Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin

10.1002/hed.26085 · 2020 · External reference

Multivalent binding and biomimetic cell rolling improves the sensitivity and specificity of circulating tumor cell capture

10.1158/1078-0432.ccr-17-3078 · 2018 · External reference

Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment

10.1016/j.canlet.2023.216187 · 2023 · External reference

Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients

10.1016/j.bios.2023.115117 · 2023 · External reference

Prospective characterization of circulating tumor cell kinetics in patients with oligometastatic disease receiving definitive intent radiation therapy

10.1200/po.23.00303 · 2023 · External reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

10.1016/j.ejca.2008.10.026 · 2009 · External reference

Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts

10.1158/1078-0432.ccr-12-2746 · 2013 · External reference

Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts

10.1371/journal.pone.0100995 · 2014 · External reference

Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients

10.1186/s12967-021-02850-1 · 2021 · External reference

Tumor dissociation to single cell suspension v1

10.17504/protocols.io.bp2l62bjkgqe/v1 · 2024 · External reference

Dictionary learning for integrative, multimodal and scalable single-cell analysis

10.1038/s41587-023-01767-y · 2024 · External reference

Complex heatmap visualization

10.1002/imt2.43 · 2022 · External reference

Fitting linear mixed-effects models using lme4

10.18637/jss.v067.i01 · 2015 · External reference

Unresolved reference

2024 · External reference

Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck

10.1093/annonc/mdt180 · 2013 · External reference

Cotargeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC

10.1158/1535-7163.mct-17-0115 · 2017 · External reference

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

10.1186/s12885-022-09511-6 · 2022 · External reference

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib

10.1016/j.xcrm.2024.101703 · 2024 · External reference

EGFR: new insights on its activation and mutation in tumor and tumor immunotherapy

10.1002/advs.202505785 · 2025 · External reference

Long-term survival and molecular biomarker evaluation of a phase II cetuximab and nivolumab clinical trial in recurrent/metastatic head and neck cancer

10.1158/1078-0432.ccr-25-2201 · 2026 · External reference

EGFR inhibition by cetuximab modulates hypoxia and IFN response genes in head and neck squamous cell carcinoma

10.1158/2767-9764.crc-22-0443 · 2023 · External reference

Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of phase I/II study

10.3390/cancers13051180 · 2021 · External reference